Kobach referenced a June 2021 warning issued by the US Food and Drug Administration regarding the elevated risks of myocarditis and pericarditis linked to Pfizer's and Moderna's Covid-19 vaccines. The lawsuit contends that Pfizer misrepresented the vaccine's ability to prevent coronavirus transmission, a claim contradicted by the company's later admission that it had not conducted studies on this aspect. Kobach argued that Pfizer's actions contributed to public confusion and undermined trust in the vaccine's true efficacy and safety profile. The legal challenge from Kansas underscores broader concerns about transparency and accountability in pharmaceutical communications during public health emergencies. As the case unfolds, it is expected to shed light on the regulatory scrutiny surrounding Covid-19 vaccines and the responsibilities of manufacturers in providing accurate information to both the public and regulatory authorities.